Acusphere, Inc. is a pharmaceutical company, which engages in the development of drugs and formulations of existing drugs using proprietary micro particle technology. The company is headquartered in Lexington, Massachusetts. The company went IPO on 2003-10-08. The firm is focused on the development of Imagify, which contains Perflubutane Polymer Microspheres for injectable suspension. The firm's product Imagify is a cardiovascular drug for the detection of coronary artery disease (CAD). Imagify injectable suspension consists of porous, synthetic polymer microspheres containing gas that are administered intravenously and act as tracers of blood flow or perfusion. The firm has submitted the Marketing Authorization Application (MAA) for its lead product candidate, Imagify lyophilisate for dispersion for injection with the European Medicines Agency (EMA) to support the regulatory review of Imagify in the European Union (EU).
Follow-Up Questions
Acusphere Inc (ACUS) 的本益比是多少?
Acusphere Inc 的本益比是 0
Acusphere Inc 的 CEO 是誰?
Mr. Mark Leuchtenberger 是 Acusphere Inc 的 President,自 2013 加入公司。
ACUS 股票的價格表現如何?
ACUS 的當前價格為 0,在上個交易日 decreased 了 0%。
Acusphere Inc 的主要業務主題或行業是什麼?
Acusphere Inc 屬於 Pharmaceuticals 行業,該板塊是 Health Care